Benzamide derivative compound, method for preparing same, and pharmaceutical composition for treating or preventing inflammatory disease containing same as active ingredient

A compound represented by Formula 1 below, an optical isomer thereof or a pharmaceutically acceptable salt thereof:

• wherein,
• L is single bond or straight or branched C1-C6 alkylene;
• R1 is hydrogen;
• C3-C8 cycloalkyl;
• substituted or unsubstituted C6-C12 aryl, wherein the substituted C6-C12 aryl is substituted with one or more substituents selected from the group consisting of halogen, —NH2, straight or branched C1-C3 alkyl, and straight or branched C1-C3 alkoxy;
• substituted or unsubstituted heteroaryl consisting of 6 to 12 atoms containing one or more heteroatoms selected from the group consisting of N and O, wherein the substituted heteroaryl consisting of 6 to 12 atoms is substituted with one or more halogens;
• or heterocycloalkyl consisting of 6 to 10 atoms containing one or more heteroatoms selected from the group consisting of N and O;
• and
• R2 is hydrogen or straight or branched C1-C3 alkyl;
• R3 is substituted or unsubstituted C6-C10 aryl, wherein the substituted C6-C10 aryl is substituted with one or more methoxy groups;
• or substituted or unsubstituted morpholinyl or piperazinyl, wherein the substituted morpholinyl or piperazinyl is substituted with one or more hydroxyl ethyl groups;
• and
• R4 is C1-C3 haloalkyl,
• or
• wherein,
• L is single bond;
• R1 is C3-C8 cycloalkyl;
• substituted or unsubstituted C6-C12 aryl, wherein the substituted C6-C12 aryl is substituted with one or more substituents selected from the group consisting of halogen, —NH2, straight or branched C1-C3 alkyl, and straight or branched C1-C3 alkoxy;
• substituted or unsubstituted heteroaryl consisting of 6 to 12 atoms containing one or more heteroatoms selected from the group consisting of N and O, wherein the substituted heteroaryl consisting of 6 to 12 atoms is substituted with one or more halogens;
• or heterocycloalkyl consisting of 6 to 10 atoms containing one or more heteroatoms selected from the group consisting of N and O;
• and
• R2 is hydrogen or straight or branched C1C3 alkyl;
• R3 is substituted C6-C10 aryl, wherein the substituted C6-C10 aryl is substituted with one or more methoxy groups;
• or substituted or unsubstituted morpholinyl or piperazinyl, wherein the substituted morpholinyl or piperazinyl is substituted with one or more hydroxyl ethyl groups;
• and
• R4 is —SR5 or SO2R5, wherein R5 is straight or branched C1-C6 alkyl,
• or
• wherein,
• L is straight or branched C1-C6 alkylene;
• R1 is substituted or unsubstituted C6-C12 aryl, wherein the substituted C6-C12 aryl is substituted with one or more substituents selected from the group consisting of halogen, —NH2, straight or branched C1-C3 alkyl, and straight or branched C1-C3 alkoxy;
• substituted or unsubstituted heteroaryl consisting of 6 to 12 atoms containing one or more heteroatoms selected from the group consisting of N and O, wherein the substituted heteroaryl consisting of 6 to 12 atoms is substituted with one or more halogens;
• or heterocycloalkyl consisting of 6 to 10 atoms containing one or more heteroatoms selected from the group consisting of N and O;
• and
• R2 is hydrogen or straight or branched C1-C3 alkyl;
• R3 is substituted or unsubstituted morpholinyl or piperazinyl, wherein the substituted morpholinyl or piperazinyl is substituted with one or more hydroxyl ethyl groups;
• and
• R4 is —SR5 or SO2R5, wherein R5 is straight or branched C1-C6 alkyl.